Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: A systematic review and meta-analysis
Silvia Belloni(IRCCS Humanitas Research Hospital), Cristina Arrigoni(University of Pavia), Arianna Magon(IRCCS Policlinico San Donato), Rosario Caruso(University of Milan), Paola Tiberio(Fondazione IRCCS Istituto Nazionale dei Tumori), Rita De Sanctis(Humanitas University), Armando Santoro(IRCCS Humanitas Research Hospital), Alberto Zambelli
Cited by 5
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
|JAMA|2014|569
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532